ArticleCurrent oncology (Toronto, Ont.)2022
Cancer Premature Mortality Costs in Europe in 2020: A Comparison of the Human Capital Approach and the Friction Cost Approach.
Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A Comparative Analysis of the Economic Burden of Breast, Colorectal and Lung Cancer-Related Premature Mortality in Slovenia: Value-Added Decomposition by Occupation-Gender Groups.Zdravstveno varstvo · 2026Article
- Primary Care Integrated Management of chronic obstructive pulmonary disease (PRIM-COPD): study protocol for a cluster-randomised controlled trial.BMJ open respiratory research · 2026Article
- Subtype-specific health and economic impact of delayed breast cancer diagnosis during the early COVID-19 pandemic in Belgium: a Markov model analysis.Breast cancer research : BCR · 2025Article
- Different attitudes towards estimating indirect costs of disease: The example of cancer.Journal of public health research · 2025Review
- Article
- Economic burden of patients with leading cancers in China: a cost-of-illness study.BMC health services research · 2024Article
- Productivity losses from short-term work absence due to neoplasms in Poland.Scientific reports · 2024Article
- Exploring the associations between adverse childhood experiences (ACEs) and adolescent cancer risk behaviours in the ALSPAC cohort.BMC public health · 2024Article
- Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018-2040.Applied health economics and health policy · 2023Article
- Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries.PharmacoEconomics · 2023Article
- Societal Perspectives and Real-World Cost-Effectiveness: Expanding the Scope of Health Economics Inquiry.Current oncology (Toronto, Ont.) · 2022Article
- Effectiveness and cost-effectiveness of an integrated digital psychological intervention (Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The inclusion of productivity costs can affect the outcome of cost-effectiveness analyses. We estimated the value of cancer premature mortality productivity costs for Europe in 2020 using the Human Capital Approach (HCA) and compared these to the Friction Cost Approach (FCA). Cancer mortality data were obtained from GLOBOCAN 2020 by sex and five-year age groups. Twenty-three cancer sites for 31 European countries were included. The HCA and the FCA were valued using average annual gross wages by sex and age group and applied to Years of Potential Productive Life Lost. 2020 friction periods were calculated and all costs were in 2020 euros. Estimated cancer premature mortality costs for Europe in 2020 were EUR 54.0 billion (HCA) and EUR 1.57 billion (FCA). The HCA/FCA cost ratio for Europe was 34.4, but considerable variation arose across countries (highest in Ireland: 64.5 v lowest in Czech Republic: 11.1). Both the HCA and the FCA ranked lung, breast and colorectal as the top three most costly cancers in Europe, but cost per death altered rankings substantially. Significant cost differences were observed following sensitivity analysis. Our study provides a unique perspective of the difference between HCA and FCA estimates of productivity costs by cancer site and country in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.